Geskey, Joseph M <br/><br/>
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?  [electronic resource] 

 -  Clinical therapeutics  Dec 2004 
 - 2130-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0149-2918 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2004.12.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Antiviral Agents--economics<br/>Hospitalization--statistics & numerical data<br/>Humans<br/>Infant, Newborn<br/>Infant, Premature<br/>Palivizumab<br/>Respiratory Syncytial Virus Infections--immunology